Pharmacokinetics of β-Methyldigoxin in Healthy Humans I: Intravenous Studies

Quantitative Assessment of the Effect of Chronic Kidney Disease on the Nonrenal Clearance of 10 Drugs After Intravenous Administration

“…No evidence for a reduction of CLnr by product inhibition (mechanism 2) was found for lidocaine in subjects with varying renal functions, even though CLnr declined in linear proportion to GFR. 59 A renal functioncorrelated decline of CLnr may be expected in subjects with CKD, but the over-60% reduction of CLnr in severe renal impairment observed in the present study for 6 drugs, not including meropenem, is unexpectedly large given the significantly smaller expressions of enzymes in the kidney relative to the liver. 57 Renal metabolism (mechanism 5) has been claimed for meropenem and cephapirin.…”

Pharmacokinetic Study of .BETA.-Methyldigoxin by Enzyme Immunoassay Using a Novel Specific Antiserum in Rats.

“…Hinderling et al have reported that Dx3 produced in the body after MDx3 administration could be detected at a ratio of about 10% to the dosage. 5,6) Our results and their reports indicate that Dx3 metabolized after MDx3 administration should bring about measurement errors at low level. Therefore, it is estimated that serum levels monitored by EIA-II after MDx3 administration provide MDx3 concentration containing Dx3.…”

Simultaneous quantification of digoxin, digitoxin, and their metabolites in serum using high performance liquid chromatography‐tandem mass spectrometry

“…In addition to digoxin and digitoxin, several other cardiac glycosides are used for treatment. For example, methyldigoxin, which is eliminated via the renal route; 25% of the given dose is found unchanged in urine and 30% is metabolized to digoxin . It is also found unchanged and demethylated in blood .…”